Pikagi
Ben Westphalen Profile Banner
Ben Westphalen Profile
Ben Westphalen

@BenWestphalen

4,319
Followers
200
Following
1,203
Media
9,579
Statuses

Oncologist focused on #PrecisionOncology 🎯 & #PancreaticCancer 💜 • @myesmo PMWG chair • #MissionCancer Board🇪🇺•Rolling with @OncoAlert 🚨 •Views are my own•

Munich
https://t.co/t5M4rlpPpg
Joined March 2012
Don't wanna be here? Send us removal request.
Pinned Tweet
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
The honour of a lifetime! As a European at heart, I’m super excited (& a little proud) to announce that I will join the @EU_Commission Mission Board for Cancer to promote the mission and to help driving the #EUCancerPlan 🇪🇺❤️
Tweet card media
Commission announces top experts to advise on EU Missions

Research and innovation - News alert

research-and-innovation.ec.europa.eu
27
8
169
Last Seen Profiles
Bish ✌

@DudefromBude

Mariah Clayton

@mclayton23

Itz_lakor

@ILakor

👸🏼MissNikkiiBaby

@MissNikkiiBaby

Andrea Waner, BA, MPA

@andreawaner

Faida Investment Bank.

@FIB_Kenya

Jaron

@JaronTalley

SNJ - premier syndicat de journalistes

@SNJ_national

1-800-FLOWERS.COM, Inc. News

@1800FLOWERSInc

CafeComRai🌵💛

@CafeComRai

Li✨

@kingjaliyaah

Bridgeworks

@BridgeworksLtd

Naiara

@naiaraconde14

Toniduklas Duklas

@Toniduklas41625

Jahmel Gordon (Bus Arrows Studios Suspended)

@Jaygee598

NotWokeTeacher

@teacher_woke

Katherine Wolfrey

@KatherineWolfr3

Wok

@Wok

Marlukee

@giezimarcelo

NYC Postdoc Coalition

@NYC_Postdoc

Dr. Flagelo

@drflagelo

Gavin Morris

@gavinmorris40

Bliss❤️ $DROIDS $XTER $PIXIZ

@_MeowKittens_

Kstylis

@Kstylis

Slender

@deas_72

soby is on xai 🎮⛓️

@sobylife

Hart County Football

@HartCountyFball

MarketingMiner [CZ] ⛏

@MktMiner

Patriot Dan

@DanielFS43

mercedesegea

@mercedesegea

౨ৎ

@ST1LLM0NSTER

Wicked UK

@WickedUK

Jen ❤️

@jennahopejacob1

ゆぬきうた

@yunuki

LACisco

@cisco_la

ポケプラ@トレカ相場情報

@pokeca_price

@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Saturday morning ☀️ wisdom…
Tweet media one
20
76
767
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Great collaborative work led to this @NatureMedicine perspective. We explore ways on how to deliver #PrecisionOncology to #patients with #Cancer 💪🏼 @quimmateo @LotteSteuten @aftimosp @FAndreMD @ProfDMThomas @OncoAlert 🚨 #PrecisionMedicine
Tweet media one
Tweet media two
5
68
180
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Most probably the biggest surprise & personally for myself, the biggest disappointment…short course neoadjuvant FOLFIRINOX did not improve OS in #patients w resectable #PancreaticCancer in NORPACT-1 w SHORTER survival in the neoadjuvant arm. #pancsm 💜 @OncoAlert 🚨 #ASCO23
Tweet media one
Tweet media two
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
LBA4005 - NORPACT-1: Short neoadjuvant FOLFIRINOX (A) vs surgery (B) for resectable #PancreaticCancer 140 #patients randomised Endpoint OS in months A: 23B: 34.4 Proceeded to surgery in A: 82% Adjuvant therapy in B: 75% #ASCO23 @OncoAlert 🚨 #pancsm 💜
0
8
14
11
60
160
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Finally out (open) in @Nature_NPJ #PrecisionOncology - results of a great collaboration w @FoundationATCG 🤝 We analysed the genomic context of NTRK fusion positive tumours in a cohort of > 295.000 #cancers Thanks to everyone involved! @OncoAlert 🚨
Tweet media one
12
40
113
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 months
Still can’t believe that this is real 🤩 I’m so honored to chair the @myESMO Translational Research & Precision Medicine Working Group for the next two years! Buckle up….we got a look of things to achieve.
Tweet media one
16
5
112
@BenWestphalen
Ben Westphalen
@BenWestphalen
11 months
3,5 million RAS mutant #cancers are diagnosed each year. Thus, targeting mutant RAS remains a major focus in expanding the reach of #PrecisionMedicine 🎯 In @nature ➡️ in depth description of a pan-RAS inhibitor. #PrecisionMedicine @OncoAlert 🚨
Tweet card media
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Nature - A non-covalent inhibitor that binds preferentially to the inactive state of KRAS while sparing NRAS and HRAS is reported, indicating that most KRAS oncoproteins cycle between an active...

www.nature.com
3
29
107
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
1/2 When a napkin idea finally becomes reality. I’m very proud to announce that we were able to enrol the 1st patient in the PROJECTION trial today. PROJECTION will investigate the prognostic role of preoperative ctDNA in patients with resectable #PancreaticCancer
Tweet media one
10
14
109
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
1/2 Took some time to go through the #ASCO23 abstracts & selected what I found most interesting in #PancreaticCancer I’d appreciate your thoughts & feedback, especially if I missed out on anything! We are all @OncoAlert 🌐 @ASCO #pancsm 💜 @Aiims1742 @PancPathologist
Tweet media one
4
40
103
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
This is big and could lead to a tectonic change in the management of #ColorectalCancer 🚀 Presented at #ASCO22 & out in the ⁦ @NEJM ⁩ ➡️Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II #crcsm @OncoAlert 🚨 #PrecisionMedicine
5
33
102
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Broad analysis of Cell-surface proteins leading to “The Cancer Surfaceome Atlas” integrating genomic, functional & drug response data. Have to read up on this in ⁦ @NatureCancer ⁩ as I clearly have a blind spot here… @OncoAlert 🚨 #PrecisionMedicine
Tweet card media
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify...

Nature Cancer - Zhang and colleagues perform systematic multiomics and functional integration of cell-surface proteins and develop a comprehensive catalog of cell-surface actionable targets across...

www.nature.com
0
34
104
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
First results of CUPISCO presented at #ESMO23 . Comprehensive genomic profiling, an MTB & targeted treatments improve progression free survival in patients w poor prognosis #cancer of unknown primary over platinum CTX. THIS IS BIG 🚀 #PrecisionMedicine @OncoAlert 🚨 #ESMO23
Tweet media one
Tweet media two
Tweet media three
Tweet media four
4
41
97
@BenWestphalen
Ben Westphalen
@BenWestphalen
9 months
The emperor of all oncogenes…once deemed undruggable... Kirsten rat sarcoma virus (KRAS). After G12C inhibitors…G12D is next… #OpenAccess #Researchpaper in @trendscancer on ongoing developments & #clinicaltrials #PrecisionMedicine @OncoAlert 🚨
Tweet card media
Next batter up! Targeting cancers with KRAS-G12D mutations

KRAS is the most frequently mutated oncogene in cancer. Activating mutations in codon 12, especially G12D, have the highest prevalence across a range of carcinomas and adenocarcinomas. With inhibit...

www.cell.com
3
47
98
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
I’m beyond excited to co-lead the L1ST (Liquid First) trial to establish the role of of liquid biopsies into routine workup of #cancer #patients together with the fantastic @barlesi of @GustaveRoussy - it’s an honor to work along such a giant in #CancerResearch 🤩 #ASCO22
Tweet media one
0
15
97
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Shocked to hear that a young colleague advised others against the concept of mentoring…mainly because „there was nothing in it for the mentors“ & thus futile. I feel „non conditional“ mentoring is a cornerstone of education. Wonder what my colleagues think? @OncoAlert 🚨
Tweet media one
19
15
93
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
The excitement when your abstract is selected as a MiniOral at @myESMO #ESMO20 congress...(👇) 🚀
5
4
90
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Learning of the day...
Tweet media one
3
8
89
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Meet (a small part of) the team: It is inspiring (and so much fun) to be part of the interdisciplinary CCC Munich @LMU_Uniklinikum precision oncology program. We have started weekly meetings of the MTB to have more time to discuss more patients. #iamandiwill #PrecisionMedicine
Tweet media one
3
8
85
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
NICHE-2 included 107 patients ✅ Pathological complete response 95%% Pathological response 67 % 61% w (mild) AEs ✅ 100% R0 resections 🤩 @OncoAlert 🚨 #ESMO22 #Immunotherapy @myESMO @MyriamChalabi
Tweet media one
Tweet media two
1
25
83
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Most of our #cancer #patients die of metastatic disease. This ⁦ @trendscancer ⁩ review puts a spotlight 💡 on recent development in this field of #cancerreaearch ⁦ @OncoAlert ⁩ 🚨
Tweet card media
Evolution of metastasis: new tools and insights

Metastasis is an evolutionary process occurring across multiple organs and timescales. Due to its continuous and dynamic nature, this multifaceted process has been challenging to investigate and...

www.cell.com
1
36
81
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Revolutionary statement hidden in plain sight: “…provide a rationale for genomic testing for ALL (‼️) solid tumors” from the @ASCO @JCO_ASCO provisional opinion on genomic testing in #patients w met/adv. #cancer @OncoAlert 🚨 #PrecisionMedicine
Tweet media one
1
24
75
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Beautiful open (!) review on the complexity of #Immunotherapy in upper gastrointestinal #cancer in @myESMO @Annals_Oncology summarizing the “2020 revolution” Thanks: @LizzySmyth1 @ValeGambardella @AndresC27622123 & @tfleitask @OncoAlert 🚨 #oncology
Tweet media one
2
19
76
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
2nd #ASCO22 take away: There is no “impossible” in #CancerResearch ✅ 🎯 HER2 low #BreastCancer ✅ Potentially curative #Immunotherapy in #colorectalcancer ✅ Biomarkers trumping histology ✅ ctDNA guided TX What are your possible impossibles? @OncoAlert 🚨
2
17
75
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
I congratulate Andrew Ko for having the guts to address the 🐘 in the room…
Tweet media one
1
13
75
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
It’s absolutely amazing to see how many active compounds targeting FGFR2 fusions are available for our patients with #BiliaryTractCancer - great slide by @ArndtVogel ⭐️ # @OncoAlert 🚨 #PrecisionMedicine @pashtoonkasi @GABOUALFA @VivekSubbiah
Tweet media one
0
21
72
@BenWestphalen
Ben Westphalen
@BenWestphalen
11 months
To advance #PrecisionOncology it is absolutely imperative to publish „negative“ results so that we can learn from each other. ➡️ @IntJCanc 🇦🇺✚🇳🇱 data on limited activity of CDK4/6❌ in #cancer #patients w CDK4/6 alts #PrecisionMedicine @OncoAlert 🚨
Tweet card media
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin...

The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.

onlinelibrary.wiley.com
4
25
70
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Now happening at #ESMO22 🔥 #PrecisionOncology super star @VivekSubbiah on tissue agnostic therapeutics in #oncology 🎯 @OncoAlert 🚨 #PrecisionMedicine
Tweet media one
0
15
71
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
#MedTwitter we need help - please re-tweet! We are searching for a clinical trial for a 16yo with NUTM1 fusion positive advanced thyroid cancer (NUT midline carcinoma) in Europe. @myESMO @OncoAlert 🚨 @BettinaRyll @VivekSubbiah @DKTK_ @pashtoonkasi @ERN_EURACAN #ERNPaedCan
9
86
65
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Super interesting! Out in @ASCO_pubs Precision Oncology - sensitising a TMB low neuroendocrine tumour to ICI through Temozolomide-induced hypermutation. > 2years of benefit from Pembrolizumab after conversion to TMB high @OncoAlert 🚨 @Dr_R_Kurzrock
7
25
68
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
What a pleasure to officially „open“ @myESMO #ESMO22 with the fantastic @darioT_ - friends & colleagues: WELCOME TO PARIS 🇫🇷
Tweet media one
2
1
69
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Super excited to record our mini oral for the @myESMO #ESMO20 virtual congress. Watch out for abstract #4143 : Pan-Cancer analysis of HRR associated gene alts & genome wide LOH 😉 Thanks to all co-authors 🤝 @quimmateo @FAndreMD @EthanSokol @Alexander_Fine @FoundationATCG
Tweet media one
Tweet media two
5
12
68
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
#PancreaticCancer still caries a dismal prognosis…we need to do better! Today we at @CccLmu @LMU_Uniklinikum show our support of #WorldPancreaticCancerDay 💜
Tweet media one
2
15
68
@BenWestphalen
Ben Westphalen
@BenWestphalen
6 months
Such an honor and a great pleasure to co-chair the @myESMO advanced course on „Biomarkers for Precision Immunotherapy-Oncology Across Tumors“ in Zurich 🇨🇭 Looking forward to great talks and „heated“ discussions 🚀
Tweet media one
2
7
68
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
The concept of Temozolomide induced hypermutation causing sensitivity towards #Immunotherapy fascinates me A case report in @ASCO @JCOPO_ASCO describes successful ICI treatment of an atypical carcinoid tumour after TMZ. # @OncoAlert 🚨 #PrecisionMedicine
Tweet card media
Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced...
ascopubs.org
2
23
67
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
KRAS mutations occur in >90% of #PancreaticCancer #patients & the G12D variant is most common. In a @AACR @CD_AACR #OpenAccess #researchpaper @sam_kemp20 & team use a G12D specific inhibitor in relevant models of #pancsm ➡️very promising💜 @OncoAlert 🚨
Tweet media one
2
24
63
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
When you try to insert an ⁦ @myESMO ⁩ background using the bluescreen feature...wearing blue scrubs. #ITfails
Tweet media one
3
0
64
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
I just had to steal it 🤣 @VivekSubbiah @HCCvPDAC
Tweet media one
1
11
65
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Sunday ☀️ morning wisdom 😉
Tweet media one
1
10
62
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
At a @CSHL meeting on #PancreaticCancer - 10 years ago…I was told that KRAS would remain undruggable In @NEJM - activity of sotorasib in #pancsm 💜 ✅ 38 heavily pretreated #cancer #patients ✅ ORR 21% ✅ PFS 4 months ✅ OS 6.9 months @OncoAlert 🚨
Tweet media one
1
16
62
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Colossal #OpenAccess #Researchpaper in @nature 🔥 Mapping the immune landscape of gliomas & brain metastases at single cell resolution 🔬 Better tx of primary & secondary 🧠 #cancers is a high unmet medical need - understanding is 🔑 @OncoAlert 🚨
Tweet card media
Single-cell spatial immune landscapes of primary and metastatic brain tumours

Nature - Imaging mass cytometry of human brain tumours provides spatial information that, combined with existing transcriptomic data, reveals the existence of a cellular neighbourhood containing a...

www.nature.com
0
24
61
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Heute ist ein ganz besonderer Tag für mich…ich darf meiner Mama beim Fundraising anlässlich des 20. Geburtstags des Kinderhospiz @sternenbruecke_ in Hamburg helfen. Kommt alle vorbei - Tag der offenen Tür von 12-18:00 @NiniBela1 @DocOnco @HSV
20 Jahre Sternenbrücke

In diesem Jahr feiert die Sternenbrücke ihr 20-jähriges Bestehen! Blicken Sie mit uns zurück auf die Meilensteine und Höhepunkte der vergangenen 20 Jahre und feiern Sie gemeinsam mit uns am 1. Mai im...

sternenbruecke.de
3
13
59
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Fantastic read for a ☀️ Sunday train ride. The 2021 @myESMO guidelines on the management of metastatic #BreastCancer #bcsm published in @Annals_Oncology 📝 Really intrigued by the clean outline helping to bring structural clarity into a complex field!
Tweet media one
2
8
60
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Let’s go☝️ The @myESMO #sarcoma and #rarecancers congress in Lugano has started - looking forward to an inspiring meeting and lots of fruitful and insightful discussions. @OncoAlert 🚨 @ERN_EURACAN @_rarecancer #ESMOSarcomaAndRareCancers23
Tweet media one
1
6
59
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
0/6 Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer . That’s why, it is important to generate solid evidence to define areas in which they can guide treatment decisions. @OncoAlert 🚨 #LiquidBiopsies #PrecisionMedicine
2
16
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Kicking of the second session 🚀 @UmbertoMalapel1 on experimental & translational techniques in #LiquidBiopsies 🩸 🧬 🎯 @OncoAlert 🚨 #PrecisionMedicine @myESMO @ChristianRolfo @SonjaLoges @pashtoonkasi PS: Umberto declared a “COI” ➡️ I’m a fan of #LiquidBiopsies ❤️
Tweet media one
2
12
60
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Great paper by @PeterHoseinMD & team in @JAMAOnc : Nivo/Ipi in #PancreaticCancer / biliary tract #cancer w path variants in HR genes: ✅ 12 #patients 😲4 CR ‼️4 CR ➡️ NED 11-41 months. ➡️ ORR 42% - DCR 58% @OncoAlert 🚨 #PrecisionMedicine #pancsm
Tweet media one
0
21
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
More data on neoadjuvant #immunotherapy in MSI-high/dMMR #Cancers out in @JCO_ASCO 👇🏼 ➡️35 #patients & 33 evaluable ✅ORR 82% 🔪17 patients underwent surgery - PCR 65% 🛑10 patients elected to continue ICI #PrecisionMedicine @OncoAlert 🚨
Tweet card media
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair...

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in...

ascopubs.org
1
24
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Ich bin fassungslos…. In Hamburg gab es Schlägereien mit Verletzungen um das verfügbare Feuerwerk, welches innerhalb von Minuten ausverkauft war. Nun wurden wir glücklicherweise mit “Notimporten” aus der Schweiz “gerettet”. @DocOnco @NiniBela1 @ABStewardess @ABStewardess
7
1
55
@BenWestphalen
Ben Westphalen
@BenWestphalen
5 months
Want to know what happened in #PrecisionOncology in 2023? Check out this brilliant #OpenAccess #researchpaper in @CD_AACR by @CDebyaniPhD & team… #PrecisionMedicine @OncoAlert 🚨 @VivekSubbiah
Tweet card media
Precision Oncology: 2023 in Review

Summary: . This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022...

aacrjournals.org
1
23
59
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Treating #PancreaticCancer remains one of the most challenging task in #Oncology . Knowing your enemy is 🔑 This @CellCellPress #researchpaper describes how the #microenvironment shapes fundamental characteristics of #pancsm @OncoAlert 🚨 #OpenAccess
Tweet media one
1
16
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Final OS results of the POLO trial in #PancreaticCancer out in @ASCO @JCO_ASCO mOS: 19.0 vs 19.2 months ➡️no difference but Median time to 1st & 2nd subsequent #cancer tx & time to discontinuation of study tx favoured olaparib. @OncoAlert 🚨 #pancsm 💜
Tweet card media
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib...

PURPOSE The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic...

ascopubs.org
10
16
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Great news for European #Cancer #Patients - the European commission has extended approval of Pembrolizumab for patients with dMMR/MSI: ✅ #GastricCancer ✅ #BiliaryTractCancer ✅ #EndometrialCancer ✅ #SmallIntestinalCancer @OncoAlert 🚨 #PrecisionMedicine #access
2
20
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
#GI21 Amazing to see how far we have come. BUT still ways to go! Kohei Shitara on the role of #PrecisionMedicine in gastrointestinal #cancers and how tumour profiling can help guide therapeutic decisions. @OncoAlert 🚨 @pashtoonkasi
Tweet media one
2
23
58
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Got 🆙 early to go for a hike in the🏔️ I found #PeaceOfMind and absolute solitude. I wish all of you a wonderful Sunday ☀️
Tweet media one
Tweet media two
2
0
57
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Such a pleasure and honor to share a selfie with #PancreaticCancer super heroes 🦸‍♀️ @KReissMD & @EileenMOReilly during the poster session at @ASCO 23 #FriendlyFaces at #ASCO23
Tweet media one
3
5
56
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Pushing #LiquidBiopsies 💪🏼 In @NatureMedicine - @Albert0Bardelli & team report on the CHRONOS trial in #colorectalcancer - aim was EGFRi re-challenge ➡️ 63% DCR @OncoAlert 🚨 #PrecisionMedicine @lonardi_sara @pashtoonkasi @FilippoPietran4 #crcsm
Tweet card media
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the...

Nature Medicine - In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with...

www.nature.com
3
18
55
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 month
#openaccess @myESMO @ESMO_Open genomic profiling in the management of #patients w rare #cancers : Rare cancer patients show favourable response to matched therapies, with a higher ORR in early treatment lines. #PrecisionMedicine @OncoAlert 🚨
Tweet card media
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profil...

Comprehensive genome profiling (CGP) serves as a guide for suitable genomically matched therapies for patients with cancer. However, little is known about the impact of the timing and types of cancer...

www.esmoopen.com
0
29
56
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
A topic every #oncologist should be familiar with: “Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy” Comprehensive review published in ⁦ @JAMANetwork ⁩ ⬇️ ⁦ @OncoAlert ⁩ 🚨
Tweet card media
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor...

This JAMA Clinical Guidelines Synopsis summarizes the National Comprehensive Cancer Network’s 2019 guidelines on management of immunotherapy-related toxicities, including adverse skin reaction,...

jamanetwork.com
1
22
56
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
1/x My 1st #ESMO23 #PrecisionMedicine highlight deserves a tweetorial. Primary analysis of CUPISCO a randomised trial of targeted tx or immunotherapy vs CTX in #cancer of unknown primary presented by @LindaMileshkin @myESMO CUP guidelines @OncoAlert 🚨
Tweet card media
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Cancer of unknown primary (CUP) is defined as a carcinoma or undifferentiated neoplasm for which a standardised diagnostic work-up fails to identify the primary tumour responsible for metastatic...

www.annalsofoncology.org
4
23
55
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
When you hit 🎯 the jackpot for one of your patients! #PrecisionMedicine
Tweet media one
4
3
55
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Out in @NEJM - results of FOENIX-CCA2 study of Futibatinib in #patients with pretreated #CholangioCarcinoma ✅103 #patients ➡️42% ORR 🤩 Median duration of response 9.7 months. 🤩PFS 9.0 months & OS 21.7 months. @OncoAlert 🚨 #PrecisionMedicine
Tweet card media
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma | NEJM

Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-gener...

www.nejm.org
0
18
52
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
So these are surprisingly good results for the SEQUENCE trial in #PancreaticCancer presented at #ASCO22 - I wonder what my #pancsm colleagues say: @KReissMD @EileenMOReilly @Aiims1742 @pashtoonkasi @PamelaKunzMD ? @OncoAlert 🚨 #pancsm 💜
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
8
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
🔥Out in @Annals_Oncology the new #Cancer of unknown primary: @myesmo Clinical Practice Guideline for diagnosis, treatment and follow-up 🤩 Congratulations to the whole team around Alwin Krämer 👏🏻 @OncoAlert 🚨 #PrecisionMedicine
Tweet media one
0
16
53
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
There are official #ESMO23 #SoMe ambassadors. Then there are other #SoMe super stars ✨ providing high quality content. If you’re interested in top coverage on #PancreaticCancer & translational #CancerResearch - be sure to follow @graokane 🇮🇪❤️ #pancsm 💜 @OncoAlert 🚨
Tweet media one
4
10
53
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Not all BRAF Mutations are equal ☝️ An interesting #researchpaper in ⁦ @CR_AACR ⁩ discusses allele & lineage specific differences in #cancer . Important resource. # @OncoAlert 🚨 #PrecisionMedicine
0
18
52
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Happy Sunday everyone ❄️ Out of the city & into the mountains for a hike in the snowy alps 🏔️ ⛄️
Tweet media one
Tweet media two
Tweet media three
4
2
53
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
#PancreaticCancer is arguably one of the biggest challenges in modern #oncology - yet we’ve learned a lot over the last years. In this #OpenAccess @CellCellPress #Researchpaper @Aiims1742 & team review what you need to know… @OncoAlert 🚨 #pancsm 💜
1
15
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Further data on neoadjuvant #Immunotherapy #OpenAccess in @JCO_ASCO ➡️ Nivo/Ipi in dMMR/MSI gastric + esophagogastric junction #Cancer ✅32 #patients 🔪29 underwent #surgery 🔥All 29 R0 🔬58,6% pCR (T0N0) @OncoAlert 🚨 @YJanjigianMD @MyriamChalabi
Tweet card media
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch...

PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy...

ascopubs.org
0
30
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Last but not least…Nimotuzumab in KRAS wild type #PancreaticCancer presented at #ASCO2022 Nimotuzumab is an anti-EGFR monoclonal antibody. @OncoAlert 🚨 #pancsm 💜 #PrecisionMedicine
Tweet media one
Tweet media two
Tweet media three
Tweet media four
2
21
52
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Fantastic #PrecisionOncology #researchpaper in @CellCellPress The @MskccCMO team investigated 25.000 #Cancer #patients to uncover genomic correlates of metastatic patterns. @OncoAlert 🚨 #PrecisionMedicine #openaccess
Tweet media one
0
16
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Merry Christmas 🎄 Stay safe - wherever you are !
Tweet media one
6
1
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Do you have a little time & are interested in #PrecisionMedicine …Why don’t you check out our @myesmo #ESMO20 MiniOral (ID 85MO): HRR gene alterations & genome-wide LOH in a pan-cancer cohort? Thanks to all authors: @quimmateo @FAndreMD @EthanSokol @Alexander_Fine @OncoAlert
Tweet media one
1
21
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
The FGFR2 #PrecisionOncology story continues. @nature ➡️ Description of truncated FGFR2 as an actionable driver in #Cancer 🤩 👀Consider FGFR2 transcripts & co-mutational landscape! Thoughts: @VivekSubbiah @ArndtVogel ? @OncoAlert 🚨 #PrecisionMedicine
Tweet card media
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Nature - Truncation of exon 18 of FGFR2 (FGFR2ΔE18) is a potent driver mutation in mice and humans, and FGFR-targeted therapy should be considered for patients with cancer expressing stable...

www.nature.com
0
17
51
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Registration for the @myESMO #MAP2021 congress is open…and it’s free 👏 The #MAP2021 scientific co-chairs @CharlesSwanton @FAndreMD @HaanenJohn have assembled a great scientific program with regards to #PrecisionMedicine #PrecisionOncology
Tweet media one
0
25
50
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
#Cooperation is key…honored to talk about the oncologists view at #ECP22 … ⁦ @myESMO ⁩ ⁦ @esp_congress ⁩
Tweet media one
1
1
50
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
Liquid biopsies have potential to change the way we diagnose, monitor & treat #cancer - BUT (!) solid evidence is needed to build confidence in technologies to integrate them into our healthcare systems Great TracerX data presented at #ESMO23 #PrecisionMedicine @OncoAlert 🚨
Tweet media one
Tweet media two
0
30
49
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
When thoracic & gastrointestinal #oncology meet there might be liquid biopsies involved 🤝 🇪🇸 🇮🇹 🇦🇷 🇩🇪 🇺🇸 Such a pleasure to meet @ChristianRolfo @UmbertoMalapel1 @SonjaLoges @dr_ponce_aix at this interdisciplinary meeting 🥰 Thanks to @MSubklewe for taking the shot 📸
Tweet media one
5
4
48
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
We are very close to the @myESMO #ESMO20 virtual congress. We will see amazing research presented on the main stage but there is so much more to see‼️ Please find my very personal #PrecisionMedicine #ESMO20 highlights attached! Happy to hear your thoughts! @OncoAlert 🚨
Tweet media one
2
21
48
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Great review on the management of BRAF-mutant metastatic #crcsm by @agrothey @mgfakih & @TaberneroJosep published in @myESMO @Annals_Oncology 👇 Guess what…open access🌟 #colorectalcancer @heinrich_kat @StintzingS @ArndtStahler @OncoAlert 🚨
Tweet card media
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidenc...

Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management. CRC, like many malignancies, is a...

www.annalsofoncology.org
0
21
48
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
In @LancetGastroHep the @AIO_Onkologie NEOLAP trial: G/Nab-pac vs G/nab-pac followed by FOLFIRINOX induction CTX in locally advanced #PancreaticCancer #pancsm Resectability was achieved in about 1/3 of pats @OncoAlert 🚨 @Fil_Bednar @MarcBesselink
Tweet media one
5
13
47
@BenWestphalen
Ben Westphalen
@BenWestphalen
3 years
Every clinical trialist should read this editor’s note by @JackWestMD in @JAMAOnc Important to remember why we conduct clinical trials & that (in most cases) a negative ph II study should not be followed by a ph III. @OncoAlert 🚨 @Alfdoc2 @APassaroMD
Tweet card media
When the Signal From Phase 2 Research Should Be a Warning Sign

The article by Akamatsu and colleagues1 in this issue of JAMA Oncology describes a phase 2 randomized clinical trial that tests the value of adding the vascular endothelial growth factor inhibitor...

jamanetwork.com
3
9
48
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
#ESMO20 KEYNOTE590 OS superior for both histology subtypes! This is BIG!!! @OncoAlert 🚨 #immunotherapy
Tweet media one
1
15
48
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Updates of the landmark KEYNOTE-158 study of pembro for MSI-H/dMMR #cancer out in @myESMO @Annals_Oncology ✅ ORR of 30.8% ✅ mDoR of 47.5 months ✅ mPFS of 3.5 months ✅ mOS of 20.1 months @OncoAlert 🚨 #PrecisionMedicine
Tweet card media
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated...

Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid...

www.annalsofoncology.org
1
16
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
There is always time to get a little bit of exercise in 🚴😉 ⁦ @MdCurioni ⁩ and I rushed to put up her poster (1412) to then hop on the bike… Don’t forget to #BeAnActiveMember here at ⁦ @myESMO ⁩ #ESMO23 #PrEvCan
Tweet media one
1
6
47
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
#ASCO22 - @PamelaKunzMD presenting the final results of ECOG-ACRIN E2211: Cape vs Cape/TMZ in pancreatic neuroendocrine tumors: Better PFS ✅ Trend towards better OS MGMT deficiency associated with response to TMZ (exploratory) ☑️ @OncoAlert 🚨 @ASCO @marklewismd
Tweet media one
Tweet media two
Tweet media three
2
14
46
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Finally hopping on the #TrainToESMO for the @myESMO #ESMO22 annual meeting 🚄 Next stop: PARIS 🇫🇷 Tagging some colleagues to fill up the train 🚂 @TeresaSAmaral @DrJonLim @aftimosp @graokane @APassaroMD @clacardone @VivekSubbiah
Tweet media one
5
4
46
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
In order to treat #PancreaticCancer & #BiliaryTractCancer right, you need to understand your #patients molecular profile. @Aiims1742 with a fantastic poster discussion here at #ASCO23 #PrecisionMedicine @OncoAlert 🚨
Tweet media one
Tweet media two
1
14
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
PRODIGE 24/CCTG PA6 was a landmark trial in the adjuvant treatment of #PancreaticCancer (original report👇🏼)‼️ #OpenAccess in @JAMAOnc ➡️ 5y outcomes: mDFS 21.4 vs 12.8 months✅ 5y dDFS 26.1% vs 19.0%😟 mOS 53.5 vs 35.5 months✅ @OncoAlert 🚨 #pancsm 💜
Tweet media one
2
19
46
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
@DocOnco Ich finds OK - viele Mails innerhalb der „Firma“ müssen gefühlt so geschrieben werden…
2
0
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
7 months
Each year…I play a little game with myself…who is the first person to meet traveling to @myESMO #ESMO23 🧐 A very pleasant surprise to bump into @FlorianLordick 😀 The best part of the game - I always win…
Tweet media one
3
3
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Is there a Twitter handle for the train *from* #ESMO22 😉? In any case - thank you very much to all of the @myESMO staff and all of you on site and online for making this an amazing experience 🤩 @OncoAlert 🚨 #PrecisionMedicine @traintoesmo
Tweet media one
3
0
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Last but not least #ESMO20 CheckMate577 Given the complex study cohort enrolling >700 patients is a huge accomplishment! Global study 🌎 🤝 Primary endpoint DFS (secondary OS). Primary endpoint reached with HR 0.69 @OncoAlert 🚨 #immunotherapy
Tweet media one
Tweet media two
Tweet media three
0
26
45
@BenWestphalen
Ben Westphalen
@BenWestphalen
6 months
Tomorrow, @FAndreMD @FerMosele & myself will kick off the new @myESMO #PrecisionMedicine webinar series „Precision Oncology: Genomics Guided Care“. You can still register here (for free):
0
11
44
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Important trial for patients with biliary tract #cancer out in @TheLancet KEYNOTE-966 Gem/Cis +/- Pembrolizumab ✅1069 #patients 📉mOS 12.7 vs. 10.9 months (HR 0.83) So is it Pembro or Durva (see 2nd tweet)? @OncoAlert 🚨
Tweet card media
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin...

Based on a statistically significant, clinically meaningful improvement in overall survival compared with gemcitabine and cisplatin without any new safety signals, pembrolizumab plus gemcitabine and...

www.thelancet.com
4
10
43
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
What great news for a Friday 💥 We will receive kickstart funding to implement a master curriculum (MSc) in #PrecisionOncology in 🇩🇪 More information & official press release to come 🎯 @OncoAlert 🚨 #PrecisionMedicine @SonjaLoges
2
4
43
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Successful targeting of KRAS G12C was a milestone in #PrecisionMedicine . However, #Cancers can develop mechanisms of resistance. A fantastic manuscript in @nature describes these mechanisms in detail. @OncoAlert 🚨 @VivekSubbiah @Dr_R_Kurzrock
1
24
43
@BenWestphalen
Ben Westphalen
@BenWestphalen
2 years
Today is #WorldPancreaticCancerDay 💜 But the fight hasn’t started today or will stop tomorrow… #PancreaticCancer will become the 2nd most common cause of #cancer related death in the next few years & we have to give all we have to stop this trajectory. @OncoAlert 🚨 #pancsm 💜
Tweet media one
0
12
43
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Quality of life data from KN966 (Gem/Cis +/- Pembro) presented at #ASCO23 Pembrolizumab DID NOT improve quality of life - this is important when assessing the clinical value of the combination. @OncoAlert 🚨 #QualityOfLife #patientsafety #patientsfirst
Tweet media one
Tweet media two
4
11
42
@BenWestphalen
Ben Westphalen
@BenWestphalen
1 year
Why is it more complex to build a digital #cancer twin 👯‍♂️ than building a space shuttle 🚀? Brilliant talk by Walter Kolch of @ucddublin @sysbioire during the second day of the translational/precision GI #oncology meeting in Freiburg.
Tweet media one
2
13
43
@BenWestphalen
Ben Westphalen
@BenWestphalen
4 years
Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phase 2 FIGHT2️⃣0️⃣2️⃣ trial. Impressive activity of pemigatinib in #cholangiocarcinoma w. FGFR2 fusios/rearrangements. #OncoAlert 🚨
Tweet media one
1
18
43